Obesity as a factor

Nutrition Reviews

Volumn 58, Issue 3 II, 2000, Pages

  Bessesen, Daniel H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN RECEPTOR;

CONFERENCE PAPER; GENETIC ANALYSIS; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; OBESITY; PHENOTYPE; WEIGHT REDUCTION;

HUMANS; INSULIN RESISTANCE; OBESITY; PHENOTYPE; WEIGHT LOSS;

EID: 0034097328     PISSN: 00296643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Abate N, Garg A, Peshock RM, et al. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995;96:88-98
2. Ludvik B, Nolan JJ, Baloga J, et al. Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes 1995;44:1121-5
3. Lemieux S, Prud'homme D, Bouchard C, et al. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996;64: 685-93
4. Lean MEJ, Han TS, Seidell JC. Impairment of health and quality of life in people with large waist circumference. Lancet 1998;351:853-6
5. Reaven GM. Role of insulin resistance in human disease. Diabetes 1998;37:1595-607
6. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998;47:699-713
7. Jensen MD, Haymond MW, Rizza RA, et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1988;83:1168-73
8. Coppack SW, Evans RD, Fisher RM, et al. Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metabolism 1992;41:264-72
9. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997;45:3-10
10. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependant NIDDM. Genetic and clinical implications. Diabetes 1995;44:863-70
11. 31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes 1998;47:381-6
12. Colberg SR, Simoneau JA, Thaete FL, Kelley DE. Skeletal muscle utilization of free fatty acids in women with visceral obesity. J Clin Invest 1995;95:1846-53
13. Kraegen EW, Clark PW, Jenkins AB, et al. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 1991;40: 1397-403
14. Pan DA, Lillioja S, Kriketos AD, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997;46:983-8
15. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997;46:1579-85
16. Koyama K, Chen G, Lee Y, Unger RH. Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol 1997;273:E708-13
17. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-8
18. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15
19. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997;389:610-4
20. Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 1997;46:451-5
21. Schreyer SA, Chua SC Jr, LeBoeuf RC. Obesity and diabetes in TNF-α receptor-deficient mice. J Clin Invest 1998;102:402-11
22. Kahn BB. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell 1998;92:593-6
23. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998;391:900-4
24. Brüning JC, Winnay J, Bonner-Weir S, et al. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 1997;88:561-72
25. Hotamisligil GS, Johnson RS, Distel RJ, et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996;274:1377-9
26. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14
27. Mukherjee R, Davies PJA, Crombie DL, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997;386:407-10
28. Argyropoulos G, Brown AM, Willi SM, et al. Effects of mutations in the human uncoupling protein 3 gene on the respiratory quotient and fat oxidation in severe obesity and type 2 diabetes. J Clin Invest 1998;102:1345-51
29. Widén E, Lehto M, Kanninen T, et al. Insulin resistance. N Engl J Med 1995;333:348-51
30. Meigs JB, D'Agostino RB Sr, Wilson PWF, et al. Risk variable clustering in the insulin resistance syndrome. Diabetes 1997;46:1594-600
31. Eckel RH. Insulin resistance: an adaptation for weight maintenance. Lancet 1992;340:1452-3
32. Swinburn BA, Nyomba BL, Saad MF, et al. Insulin resistance associated with lower rates of weight gain in Pima Indians. J Clin Invest 1991;88:168-73
33. Valdez R, Mitchell BD, Haffner SM, et al. Predictors of weight change in a bi-ethnic population. The San Antonio Heart Study. Int J Obes 1994;18:85-91
34. Bessesen DH, Rupp CL, Eckel RH. Dietary fat is shunted away from oxidation, toward storage in obese zucker rats. Obes Res 1995;3:179-89
35. Ranneries C, Bülow J, Buemann B, et al. Fat metabolism in formerly obese women. Am J Physiol 1998;274:E155-61
36. Torjesen PA, Birkeland KI, Anderssen SA, et al. Lifestyle changes may reserve development of the insulin resistance syndrome. Diabetes Care 1997; 20:26-31
37. Markovic TP, Jenkins AB, Campbell LV, et al. The determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM. Diabetes Care 1998;21:687-94
38. Marks SJ, Moore NR, Clark ML, et al. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of Dexfenfluramine in NIDDM. Obes Res 1996;4:1-7
39. Hollander PA, Elbein SC, Hirsch IB, et al. Role of Orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998;21:1288-94
40. Guare JC, Wing RR, Grant A. Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss. Obes Res 1995;3:329-35